Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,753.60
(
-0.18%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.41
(
3.59%
)
Bitcoin
70,503.02
(
-1.04%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Double_Bagel post# 124029

Wednesday, 07/27/2011 11:13:58 PM

Wednesday, July 27, 2011 11:13:58 PM

Post# of 257257

At what point would TEVA start to get interesting even with the threat of generic Copaxone and no Teva Lovenox? At $40? At $35?

The answer depends on whether you think Teva will meet the 2015 sales and earnings guidance set forth in #msg-56956538.

Do you think they can?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now